As of May 2026, Asian markets have shown resilience with Chinese equities advancing and Japan's indices reaching record highs, driven by strong domestic demand and optimism in technology sectors. In this environment, identifying undervalued stocks can be an attractive strategy for investors seeking opportunities where market prices may not fully reflect a company's intrinsic value.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Yurtec (TSE:1934) |
¥2502.00 |
¥4951.78 |
49.5% |
| Tfe (KOSDAQ:A425420) |
₩60600.00 |
₩119827.16 |
49.4% |
| Strike Group (TSE:6196) |
¥1202.00 |
¥2354.88 |
49% |
| SMS (TSE:2175) |
¥1717.00 |
¥3364.57 |
49% |
| Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) |
HK$460.80 |
HK$898.42 |
48.7% |
| Nanya Technology (TWSE:2408) |
NT$321.00 |
NT$623.03 |
48.5% |
| Moshi Moshi Retail Corporation (SET:MOSHI) |
THB35.25 |
THB68.09 |
48.2% |
| Info-Tech Systems (SGX:ITS) |
SGD0.985 |
SGD1.92 |
48.7% |
| Beijing Luzhu Biotechnology (SEHK:2480) |
HK$19.90 |
HK$39.16 |
49.2% |
| AlbaLinkLtd (TSE:5537) |
¥2101.00 |
¥4092.89 |
48.7% |
We're going to check out a few of the best picks from our screener tool.
San Miguel Food and Beverage
Overview:San Miguel Food and Beverage, Inc. manufactures and markets processed meat products with a market cap of ₱310.23 billion.
Operations:The company generates revenue from three main segments: Food, which accounts for ₱154.08 billion; Beverage, contributing ₱146.79 billion; and Beer, with ₱136.21 billion in earnings.
Estimated Discount To Fair Value:32%
San Miguel Food and Beverage, Inc. is trading at ₱52.5, significantly below its estimated future cash flow value of ₱77.21, suggesting undervaluation based on cash flows. Recent earnings show solid growth with net income rising to PHP 7.84 billion for Q1 2026 from PHP 7.51 billion a year ago, alongside revenue growth outpacing the market at an expected annual rate of 20.8%. However, its dividend track record remains unstable despite potential profit expansion forecasted at 23.7% annually over three years.
Biocytogen Pharmaceuticals (Beijing)
Overview:Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of novel antibody-based drugs and pre-clinical research services globally, with a market cap of approximately HK$45.73 billion.
Operations:Biocytogen Pharmaceuticals generates revenue through its research and development of novel antibody-based drugs and pre-clinical research services across China, the United States, and other international markets.
Estimated Discount To Fair Value:34%
Biocytogen Pharmaceuticals (Beijing) is trading at HK$55.5, below its estimated future cash flow value of HK$84.05, indicating undervaluation. The company reported strong Q1 2026 earnings with net income reaching CNY 104.03 million from a loss last year, supported by strategic partnerships enhancing its antibody discovery platforms. Despite high share price volatility, revenue and profit are forecasted to grow significantly faster than the Hong Kong market over the next three years.
Flat Glass Group
Overview:Flat Glass Group Co., Ltd. manufactures and sells glass products across China, Asia, Europe, North America, and internationally with a market cap of HK$33.70 billion.
Operations:Revenue Segments (in millions of CN¥): The company generates revenue through the manufacture and sale of glass products across various regions including China, Asia, Europe, and North America.
Estimated Discount To Fair Value:44.3%
Flat Glass Group is trading at HK$9.17, significantly below its estimated future cash flow value of HK$16.45, highlighting potential undervaluation. Despite a decline in Q1 2026 earnings and revenue, the company's annual profit is expected to grow by 29% over the next three years, outpacing the Hong Kong market's growth rate. However, it faces challenges with high debt levels and a forecasted low return on equity of 6.5%.
Make It Happen
-
Click here to access our complete index of 196 Undervalued Asian Stocks Based On Cash Flows .
-
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
-
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Interested In Other Possibilities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PSE:FB SEHK:2315 and SEHK:6865.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
